Zifi CV 100 DT

Cefixime, sold under the brand name Suprax among others, is an antibiotic medication used to treat a number of bacterial infections. These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease. For gonorrhea typically only one dose is required. In the United States it is a second-line treatment to ceftriaxone for gonorrhea. It is taken by mouth.

Cefixime is an orally administered third-generation cephalosporin antibiotic used to treat a range of bacterial infections caused by susceptible Gram-negative and Gram-positive organisms.[1] It belongs to the beta-lactam class of antibiotics and is marketed under the brand name Suprax, among others.[2] It is on the World Health Organization's List of Essential Medicines (21st list, 2019).[3] Developed by Lederle Laboratories and patented in 1979, cefixime received approval from the U.S. Food and Drug Administration (FDA) in 1989 for treating conditions such as uncomplicated urinary tract infections, otitis media, pharyngitis, tonsillitis, and acute exacerbations of chronic bronchitis.[4][5] Cefixime is effective against certain bacterial respiratory infections, such as acute bacterial exacerbations of chronic bronchitis, which can cause severe cough. However, most severe coughs are viral or non-bacterial (e.g., acute bronchitis, common cold), where cefixime is not effective and unnecessary use can lead to antibiotic resistance. It should only be used for confirmed susceptible bacterial infections.[6][7] The 2025 Infectious Diseases Society of America (IDSA) guidelines include cefixime as an oral antibiotic option for complicated urinary tract infections (cUTIs), with a dose of 400 mg once daily for patients with normal renal function, particularly as step-down therapy from intravenous antibiotics in clinically improving patients.[8]